Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Besponsa (inotuzumab ozogamicin)
pCPA File Number:
21057
Negotiation Status:
Concluded with an LOI
Indication(s):
Acute Lymphoblastic Leukemia
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
pCODR 10121
pCPA Engagement Letter Issued:
2018-09-07
Negotiation Process Concluded:
2019-02-06